Polycythemia Vera and Other Myeloproliferative Diseases Flashcards
role of chemotherapy in reducing RBC mass in PV
no role
Coagulation studies in ET
PT and aPTT are normal
So2 in PV
Normal
synonyms for chronic PMF
idiopathic myelofibrosis
agnogenic myeloid metaplasia
myelofibrosis with myeloid metaplasia
Most common Chronic myeloproliferative disorder
PV
Causes of microcytic erythrocytosis
ß thalassemia trait
hypoxic erythrocytosis
PV
Treatment of erythromelalgia
salicylates
Anagrelide
Phosphodiesterase inhibitor
Feature of red cell mass elevation in PV
SYSTOLIC hypertension
Non malignant causes of myelofibrosis
HIV infection
Hyperparathyroidism
Renal osteodystrophy
Systemic lupus erythematosus
Tuberculosis
Vitamin D deficiency
Thorium dioxide exposure
Gray platelet syndrome
WHO Classification of Chronic Myeloproliferative Disorders
Chronic myelogenous leukemia, bcr-abl–positive
Chronic neutrophilic leukemia
Chronic eosinophilic leukemia, not otherwise specified
Polycythemia vera
Primary myelofibrosis
Essential thrombocytosis
Mastocytosis
Myeloproliferative neoplasms, unclassifiable
Anticoagulants in PV
Only if thrombosis occurs
monitoring of PT,aPTT is difficult with erythrocytosis
least common chronic MPD
PMF
Causes of relative erythrocytosis
Dehydration
diuretics
alcohol
androgen
tobacco
Tumors causing absolute erythrocytosis?
Hypernephroma
hepatoma
cerebellar hemangioblastoma
uterine myoma
adrenal tumors
meningioma
pheochromocytoma
Treatment of hyperuricemia in PV
No Rx for asymptomatic hyperuricemia< 10mg%
admn allopurinol when chemotherapy is started
Features of exuberant extramedullary hematopoeisis in pmf
ascites
portal/pulmonary/intracranial hypertension
intestinal or ureteral obstruction
cardiac tamponade
spinal cord compression
Why Hydroxyurea is effective in preventing TIA
It is a NO donor
Diagnosis and management of acquired vWF deficiency in ET
Ristocetin cofactor assay
Avoid aspirin
Treat with epsilon aminocaproic acid
Translocation in CNL
t(15;19)
anagrelide in PV
Reduces platelet count
prevents thrombosis
no marrow toxicity
Common mutation in PV,PMF,ET
JAK2 mutation,V617F
Only symptom that distinguishes PV from other causes of erythrocytosis
aquagenic pruritis
Target Hb level in PV
Males:
females:
Cause of pruritis in PV?
basophil activaton by JAK2 mutation
Phenotypic correlation of mpl mutation in PMF
more anemia
Blood picture characteristic of PV
erythrocytosis
thrombocytosis
leukocytosis
sex prediliction for ET
females
Drugs effective for prevention of TIA in ET
Hydroxyurea and aspirin are more effective than anagrelide and aspirin but not more effective for the prevention of other types of arterial thrombosis and are actually less effective for venous thrombosis
Factor essential for transformation of ET to PV
JAK2 mutation
bone x rays in PMF
osteosclerosis
Bleeding disorder caused by PV
acquired von wilibrand disease
adsorption and proteolysis of high-molecular-weight von Willebrand factor (vWF) multimers by the expanded platelet mass
Absent bone marrow iron in the presence of marrow hypercellularity
polycythemia vera
Hypoxic causes of absolute erythrocytosis
High altitude
R to L shunts
Hepatopulmonary syndrome
High affinity Hb
pulmonary disease
sleep apnea syndrome
mutations in PMF
JAK2
MPL(thrombopoeitin receptor)
role of salicylates in prevention of thrombosis in PV?
No role
Demography of PMF
male,60 yrs and above
risk factors for poor prognosis in PMF
Age >65 years
Constitutional symptoms
Hemoglobin
WBC >25 x 109/L
Blood blasts >10%
In PV,Intraabdominal venous thrombosis is common in
women
Why RBC mass and plasma volume determinations are essential in PV?
Plasma volume expansion in PV may mask elevated red cell mass
Myelofibrosis in PV
Myelofibrosis appears to be part of the natural history of the disease but is a reactive, reversible process that does not itself impede hematopoiesis and by itself has no prognostic significance
migrane that occurs in PV
ocular migrane
Malignant disorders causing myelofibrosis
Acute leukemia (lymphocytic, myelogenous, megakaryocytic)
Chronic myelogenous leukemia
Hairy cell leukemia
Hodgkin’s disease
Idiopathic myelofibrosis
Lymphoma
Multiple myeloma
Myelodysplasia
Metastatic carcinoma
Polycythemia vera
Systemic mastocytosis
unique feature of megakaryocytes
endomitotic reduplication
risk of GI bleeding is increased if aspirin is combined with which drug in ET?
anagrelide
Hypoxic erythrocytosis with normal So2
High oxygen affinity Hb disorder
Role of BMA and biopsy in PV
Provide no specific diagnostic information since these may be normal or indistinguishable from ET or PMF
Renal diseases causing absolute erythrocytosis
Renal artery stenosis
Focal sclerosing or membranous glomerulonephritis
Postrenal transplantation
Renal cysts
Bartter’s syndrome
Stress erythrocytosis
gaisbock syndrome
Type of thrombosis in PV
Venous or arterial
Both
Only test to distinguish between PV and ET is
RBC mass and plasma volume determination
cytogenetic abnormalities commonly associated with PV
trisomy 8,trisomy 9
20q-
Frequency of phlebotomy in polycythemia vera
Till iron deficiency is induced
after that once in 3 months
LDH in pmf
elevated
JAK2 is cognate tyrosine kinase for
erythropoietin and thrombopoietin receptor
Bone marrow studies in ET
BMA may be dry
Bone marrow biopsy: megakaryocyte hyperplasia and hypertrophy, as well as an overall increase in marrow cellularity
Age group affected in PV
all age groups
Lab artifacts due to ET
Hyperkalemia
Arterial O2 measurements
Difference between true erythrocytosis and plasma volume contraction
Hb> 20g/dl or HCT> 60
MPD commonly associated with night sweats, fatigue, and weight loss
PMF
Spleen in ET
Mild
Massive splenomegaly is indicative of another MPD, in particular PV, PMF, or CML
Chronic MPNs that are a diagnosis of exclusion
PMF
ET
myelophthisis
marrow fibrosis secondary to tumor or granuloma
PV pts more prone to thrombosis are
Those with massive splenomegaly
erythrocytosis masked by increased plasma volume
Features favouring MDS over ET
anemia
ringed sideroblasts
autoimmune abnormalities in PMF
ANA
RF
positive coombs test

extramedullary hematopoisis
tear drop RBC
Indications for treatment of thrombocytosis in PV
bleeding diathesis
ocular migrane
erythromelalgia
Which correlates with thrombosis in PV?
erythrocytosis or thrombocytosis
erythrocytosis
Causes of anemia in PV
GI bleed due to PUD
Leukemic transformation
massive splenomegaly(plasma volume expansion)
Cause of microcytic hypochromic anemia in PV
occult GI bleed due to PUD
Pulmonary complication in PV
Pulmonary hypertension due to fibrosis and extramedullary hematopoeisis
Absolute erythrocytosis with elevated plasma erythropoeitin
Hypoxic or autonomous erythropoietion production
location of JAK2 gene
chromosome 9p
PV should be suspected in any patient who develops
hepatic vein thrombosis
PMF pts with JAK2 mutations
50%
familial causes(with normal Hb function) of absolute erythrocytosis
Erythropoietin receptor mutation
VHL mutations (Chuvash polycythemia)
2,3-BPG mutation
LAP in PMF
low, normal, or high
Number of circulating CD34+ cells in PMF
>15,000/µL
LAP score in PV
elevated
cytogenetics in PMF
9p-
13q-
20q-
trisomy 8,9
partial trisomy 1q
Blood smear in PMF
teardrop/nucleated RBCs
myelocytes,promyelocytes,myeloblasts
anemia(occurs as a rule)
leukocyte and platelet count may be normal or increased or depressed
development of leukemia in PV is related to
chemotherapy
development of extramedullary hematopoeisis,hepatosplenomegaly,transfusion dependant anemia
Blood studies in ET
Anemia is uncommon
Mild neutrophilic leukocytosis may be seen
Preferred bcr-abl assay in thrombocytosis patients with negative cytogenetic study for philadelphia chromosome
FISH
bcr-abl reverse transcriptase polymerase chain reaction is associated with false-positive results
drugs used in PV
Interferon alpha(reduces splenomegaly)
Pegylated IFN
Hydroxyurea
anagrelide
Difference btw JAK2 mutation positive and negative Myeloproliferative disorders
JAK2 mutation positive
Disease course in decades
transformation to acute leukemia is rare
hepatomegaly in PMF
Mild hepatomegaly may accompany the splenomegaly but is unusual in the absence of splenic enlargement
ET complication that requires reduction in platelet count
migrane
Negative predictive value of plasma erythropoeitin in erythrocytosis
low
A normal erythropoietin level does not exclude a secondary cause for erythrocytosis or PV
Rx of pruritis in PV
anti histaminics
anti depressants like doxepin
hydroxy urea
Interferon alpha
PUVA
Comparison of erythropoietin and thrombopoietin

Is JAK V617F mutation diagnostic of PV?
NO
Not every patient with PV expresses this mutation, while patients without PV do
Neurologic symptoms in PV
Due to Hyperviscosity
headache
vertigo
tinnitus
visual disturbance
TIA

marrow fibrosis
Rx of polycythemia vera
phlebotomy
Drugs causing absolute erythrocytosis?
Androgens
Recombinant erythropoietin
Diff btw ß thalassemia trait and other causes of microcytic erythrocytosis
normal RDW
Increased RDW in other causes due to iron deficiency
Clinical features of PV
Splenomegaly
Hyperviscosity syndrome
thrombosis
Systolic hypertension
Hyperuricemia: secondary gout,uric acid stones
Thrombocytosis complications:
Digital ischemia
epistaxis
easy bruising
PUD
GI hemorrhage
Erythromelalgia(Erythema,burning and pain in extremities)
Cytogenetics in CEL
deletion or balanced translocation involving PDGFR alpha
Increase in marrow reticulin in ET
consider alternative diagnosis
Factors necessary for megakaryopoeisis
IL-3
SCF
SDF-1(stromal cell derived factor)
Thrombosis of which vessels commonly occurs in PV
cerebral
cardiac
mesenteric
Causes of thrombocytosis
collagen vascular disease, inflammatory bowel disease
malignancy
infection
Myeloproliferative disorders: polycythemia vera, primary myelofibrosis, essential thrombocytosis, chronic myelogenous leukemia
Myelodysplastic disorders: 5q-syndrome, idiopathic refractory sideroblastic anemia
Postsplenectomy or hyposplenism
hemorrhage
iron deficiency anemia
hemolysis
surgery
rebound:Correction of vitamin B12 or folate deficiency, post-ethanol abuse
Thrombopoietin overproduction, constitutive Mpl activation
Glucocorticoids in PMF
improvement of anemia when used alone or with thalidomide
control constitutional symptoms
autoimmune complications
Splenectomy in PMF
increase risk blastic transformation
Lymphadenopathy in PMF
isolated lymphadenopathy should suggest another diagnosis